{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:41:35Z","timestamp":1792190495492,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sun Yat-sen University Clinical Research 5010 Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Retinitis pigmentosa (RP) is characterized by progressive photoreceptor cells death accelerated by the proliferation and activation of microglia pathologically. No consensus exists on the treatment. Minocycline is recognized as a microglia inhibitor with great anti-inflammatory and neuro-protective functions. However, efficacy of minocycline in RP patients is lacking. We conducted a prospective, open-label, and single-arm trial, in which daily oral minocycline of 100\u2009mg was administered for 12 months in RP patients with light-adapted 30\u2009Hz flicker electroretinography (ERG) amplitude &gt;0\u2009\u00b5V in at least one eye (NCT04068207). The primary outcome was the proportion of participants with improvement in the ERG amplitude at month 12. The secondary outcomes included improvements of the following items: other ERGs amplitudes, visual field, best-corrected visual acuity, contrast sensitivity, color vision, and NEI-VFQ-25. 35 of 288 patients met inclusive criteria were enrolled (median [IQR] age, 36 [31\u201345] years; 17 female [48.6%]). 32 participants completed all examinations, while 3 participants completed the 12-month online visit via conducting NEI-VFQ-25. The primary outcome showed improvement was 34.3% (12 of 35 [95% CI 19.1\u201352.2]). Similarly, all secondary outcomes showed improvements. Adverse events were reported in 22 participants (62.9%) and were all resolved without extra medication during the study period. No severe adverse events were recorded. Our findings identified daily oral minocycline of 100\u2009mg for 12 months was beneficial in improving the visual function of RP patients with good safety. This study indicates minocycline may be a promising therapy for RP, but a randomized controlled trial is still needed of further exploration.<\/jats:p>","DOI":"10.1038\/s41392-024-02037-2","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T23:01:54Z","timestamp":1733266914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of minocycline in retinitis pigmentosa: a prospective, open-label, single-arm trial"],"prefix":"10.1038","volume":"9","author":[{"given":"Yuxi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0506-6362","authenticated-orcid":false,"given":"Wenru","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minzhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenjin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangwei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixian","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangxin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7617-0204","authenticated-orcid":false,"given":"Dan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"2037_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ajo.2017.01.014","volume":"176","author":"K-H Na","year":"2017","unstructured":"Na, K.-H. et al. Prevalence, age at diagnosis, mortality, and cause of death in retinitis pigmentosa in Korea\u2014a nationwide population-based study. Am. J. Ophthalmol. 176, 157\u2013165 (2017).","journal-title":"Am. J. Ophthalmol."},{"key":"2037_CR2","doi-asserted-by":"publisher","first-page":"e649","DOI":"10.1111\/j.1755-3768.2012.02396.x","volume":"90","author":"V Nangia","year":"2012","unstructured":"Nangia, V., Jonas, J. B., Khare, A. & Sinha, A. Prevalence of retinitis pigmentosa in India: the Central India Eye and Medical Study. Acta Ophthalmol. 90, e649\u2013e650 (2012).","journal-title":"Acta Ophthalmol."},{"key":"2037_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.preteyeres.2018.03.005","volume":"66","author":"SK Verbakel","year":"2018","unstructured":"Verbakel, S. K. et al. Non-syndromic retinitis pigmentosa. Prog. Retin Eye Res. 66, 157\u2013186 (2018).","journal-title":"Prog. Retin Eye Res."},{"key":"2037_CR4","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamaophthalmol.2018.0590","volume":"136","author":"EL Berson","year":"2018","unstructured":"Berson, E. L., Weigel-DiFranco, C., Rosner, B., Gaudio, A. R. & Sandberg, M. A. Association of vitamin A supplementation with disease course in children with retinitis pigmentosa. JAMA Ophthalmol. 136, 490\u2013495 (2018).","journal-title":"JAMA Ophthalmol."},{"key":"2037_CR5","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/archopht.1993.01090060049022","volume":"111","author":"EL Berson","year":"1993","unstructured":"Berson, E. L. et al. A randomized trial of vitamin A and vitamin E supplementation for retinitis pigmentosa. Arch. Ophthalmol. 111, 761\u2013772 (1993).","journal-title":"Arch. Ophthalmol."},{"key":"2037_CR6","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1136\/bjo.2009.167049","volume":"94","author":"Y Rotenstreich","year":"2010","unstructured":"Rotenstreich, Y., Harats, D., Shaish, A., Pras, E. & Belkin, M. Treatment of a retinal dystrophy, fundus albipunctatus, with oral 9-cis-beta-carotene. Br. J. Ophthalmol. 94, 616\u2013621 (2010).","journal-title":"Br. J. Ophthalmol."},{"key":"2037_CR7","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1001\/jamaophthalmol.2014.1634","volume":"132","author":"DR Hoffman","year":"2014","unstructured":"Hoffman, D. R. et al. Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): a randomized clinical trial. JAMA Ophthalmol. 132, 866\u2013873 (2014).","journal-title":"JAMA Ophthalmol."},{"key":"2037_CR8","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1172\/JCI132990","volume":"130","author":"PA Campochiaro","year":"2020","unstructured":"Campochiaro, P. A. et al. Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial. J. Clin. Investig. 130, 1527\u20131541 (2020).","journal-title":"J. Clin. Investig."},{"key":"2037_CR9","doi-asserted-by":"publisher","first-page":"7481","DOI":"10.3390\/ijms24087481","volume":"24","author":"X-T-A Nguyen","year":"2023","unstructured":"Nguyen, X.-T.-A. et al. Retinitis pigmentosa: current clinical management and emerging therapies. Int J. Mol. Sci. 24, 7481 (2023).","journal-title":"Int J. Mol. Sci."},{"key":"2037_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00963-6","volume":"7","author":"L Huang","year":"2017","unstructured":"Huang, L. et al. Mutation screening in genes known to be responsible for retinitis pigmentosa in 98 small Han Chinese families. Sci. Rep. 7, 1948 (2017).","journal-title":"Sci. Rep."},{"key":"2037_CR11","doi-asserted-by":"publisher","first-page":"100861","DOI":"10.1016\/j.preteyeres.2020.100861","volume":"79","author":"FPM Cremers","year":"2020","unstructured":"Cremers, F. P. M., Lee, W., Collin, R. W. J. & Allikmets, R. Clinical spectrum, genetic complexity and therapeutic approaches for retinal disease caused by ABCA4 mutations. Prog. Retin Eye Res. 79, 100861 (2020).","journal-title":"Prog. Retin Eye Res."},{"key":"2037_CR12","doi-asserted-by":"publisher","first-page":"14456","DOI":"10.3390\/ijms150814456","volume":"15","author":"Y He","year":"2014","unstructured":"He, Y. et al. Recent advances of stem cell therapy for retinitis pigmentosa. Int J. Mol. Sci. 15, 14456\u201314474 (2014).","journal-title":"Int J. Mol. Sci."},{"key":"2037_CR13","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/s42003-022-04016-1","volume":"5","author":"J Kralik","year":"2022","unstructured":"Kralik, J., van Wyk, M., Stocker, N. & Kleinlogel, S. Bipolar cell targeted optogenetic gene therapy restores parallel retinal signaling and high-level vision in the degenerated retina. Commun. Biol. 5, 1116 (2022).","journal-title":"Commun. Biol."},{"key":"2037_CR14","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.4103\/1673-5374.251204","volume":"14","author":"J Di Pierdomenico","year":"2019","unstructured":"Di Pierdomenico, J., Garcia-Ayuso, D., Agudo-Barriuso, M., Vidal-Sanz, M. & Villegas-Perez, M. P. Role of microglial cells in photoreceptor degeneration. Neural Regen. Res. 14, 1186\u20131190 (2019).","journal-title":"Neural Regen. Res."},{"key":"2037_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","volume":"9","author":"HS Kwon","year":"2020","unstructured":"Kwon, H. S. & Koh, S.-H. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl. Neurodegener. 9, 42 (2020).","journal-title":"Transl. Neurodegener."},{"key":"2037_CR16","doi-asserted-by":"publisher","first-page":"7815","DOI":"10.3390\/ijms22157815","volume":"22","author":"A Sanchez-Cruz","year":"2021","unstructured":"Sanchez-Cruz, A. et al. Tlr2 gene deletion delays retinal degeneration in two genetically distinct mouse models of retinitis pigmentosa. Int J. Mol. Sci. 22, 7815 (2021).","journal-title":"Int J. Mol. Sci."},{"key":"2037_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bph.12139","volume":"169","author":"N Garrido-Mesa","year":"2013","unstructured":"Garrido-Mesa, N., Zarzuelo, A. & Galvez, J. Minocycline: far beyond an antibiotic. Br. J. Pharm. 169, 337\u2013352 (2013).","journal-title":"Br. J. Pharm."},{"key":"2037_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-015-0431-4","volume":"12","author":"R Scholz","year":"2015","unstructured":"Scholz, R. et al. Minocycline counter-regulates pro-inflammatory microglia responses in the retina and protects from degeneration. J. Neuroinflammation 12, 209 (2015).","journal-title":"J. Neuroinflammation"},{"key":"2037_CR19","doi-asserted-by":"publisher","first-page":"8139","DOI":"10.1523\/JNEUROSCI.5200-13.2014","volume":"34","author":"B Peng","year":"2014","unstructured":"Peng, B. et al. Suppression of microglial activation is neuroprotective in a mouse model of human retinitis pigmentosa. J. Neurosci. 34, 8139\u20138150 (2014).","journal-title":"J. Neurosci."},{"key":"2037_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112703","volume":"139","author":"Y Shi","year":"2024","unstructured":"Shi, Y. et al. Minocycline prevents photoreceptor degeneration in retinitis pigmentosa through modulating mitochondrial homeostasis. Int Immunopharmacol. 139, 112703 (2024).","journal-title":"Int Immunopharmacol."},{"key":"2037_CR21","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1056\/NEJMoa1608889","volume":"376","author":"LM Metz","year":"2017","unstructured":"Metz, L. M. et al. Trial of minocycline in a clinically isolated syndrome of multiple sclerosis. N. Engl. J. Med. 376, 2122\u20132133 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2037_CR22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/mds.20018","volume":"19","author":"M Thomas","year":"2004","unstructured":"Thomas, M., Ashizawa, T. & Jankovic, J. Minocycline in Huntington\u2019s disease: a pilot study. Move Disord. 19, 692\u2013695 (2004).","journal-title":"Move Disord."},{"key":"2037_CR23","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1212\/01.wnl.0000201252.57661.e1","volume":"66","author":"NN-P Investigators","year":"2006","unstructured":"Investigators, N. N.-P. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66, 664\u2013671 (2006).","journal-title":"Neurology"},{"key":"2037_CR24","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s00417-023-05986-6","volume":"261","author":"AD Dave","year":"2023","unstructured":"Dave, A. D. et al. Oral minocycline for the treatment of retinitis pigmentosa-associated cystoid macular edema: results of a phase I\/II clinical trial. Graefes Arch. Clin. Exp. Ophthalmol. 261, 2209\u20132220 (2023).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"2037_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.06.003","volume":"51","author":"E Vecino","year":"2016","unstructured":"Vecino, E., Rodriguez, F. D., Ruzafa, N., Pereiro, X. & Sharma, S. C. Glia\u2013neuron interactions in the mammalian retina. Prog. Retin Eye Res. 51, 1\u201340 (2016).","journal-title":"Prog. Retin Eye Res."},{"key":"2037_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1167\/iovs.64.3.35","volume":"64","author":"N Wu","year":"2023","unstructured":"Wu, N. et al. Lithium chloride exerts anti-inflammatory and neuroprotective effects by inhibiting microglial activation in LPS-induced retinal injury. Investig. Ophthalmol. Vis. Sci. 64, 35 (2023).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"2037_CR27","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1002\/glia.23016","volume":"64","author":"KZ Matthew","year":"2016","unstructured":"Matthew, K. Z. et al. Microglial phagocytosis and activation underlying photoreceptor degeneration is regulated by CX3CL1-CX3CR1 signaling in a mouse model of retinitis pigmentosa. Glia 64, 1479\u20131491 (2016).","journal-title":"Glia"},{"key":"2037_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.toxlet.2024.08.003","volume":"400","author":"X Li","year":"2024","unstructured":"Li, X. et al. The role of BTG2\/PI3K\/AKT pathway-mediated microglial activation in T-2 toxin-induced neurotoxicity. Toxicol. Lett. 400, 81\u201392 (2024).","journal-title":"Toxicol. Lett."},{"key":"2037_CR29","first-page":"319","volume":"8","author":"KT Brown","year":"1969","unstructured":"Brown, K. T. The electroretinogram its components and their origins. UCLA Forum Med. Sci. 8, 319\u2013378 (1969).","journal-title":"UCLA Forum Med. Sci."},{"key":"2037_CR30","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1167\/iovs.13-12657","volume":"55","author":"LN Ayton","year":"2014","unstructured":"Ayton, L. N. et al. Assessing residual visual function in severe vision loss. Investig. Ophthalmol. Vis. Sci. 55, 1332\u20131338 (2014).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"2037_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ajo.2005.02.038","volume":"140","author":"MA Sandberg","year":"2005","unstructured":"Sandberg, M. A., Gaudio, A. R. & Berson, E. L. Disease course of patients with pericentral retinitis pigmentosa. Am. J. Ophthalmol. 140, 100\u2013106 (2005).","journal-title":"Am. J. Ophthalmol."},{"key":"2037_CR32","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1167\/iovs.06-0971","volume":"48","author":"MA Sandberg","year":"2007","unstructured":"Sandberg, M. A., Rosner, B., Weigel-DiFranco, C., Dryja, T. P. & Berson, E. L. Disease course of patients with X-linked retinitis pigmentosa due to RPGR gene mutations. Investig. Ophthalmol. Vis. Sci. 48, 1298\u20131304 (2007).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"2037_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1167\/tvst.9.13.29","volume":"9","author":"TA Arsiwalla","year":"2020","unstructured":"Arsiwalla, T. A. et al. Assessing residual cone function in retinitis pigmentosa patients. Transl. Vis. Sci. Technol. 9, 29 (2020).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"2037_CR34","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1167\/iovs.09-4891","volume":"51","author":"SK Holfort","year":"2010","unstructured":"Holfort, S. K., Klemp, K., Kofoed, P. K., Sander, B. & Larsen, M. Scotopic electrophysiology of the retina during transient hyperglycemia in type 2 diabetes. Investig. Ophthalmol. Vis. Sci. 51, 2790\u20132794 (2010).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"2037_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep30523","volume":"6","author":"Y Yaguchi","year":"2016","unstructured":"Yaguchi, Y. et al. Electroretinographic effects of retinal dragging and retinal folds in eyes with familial exudative vitreoretinopathy. Sci. Rep. 6, 30523 (2016).","journal-title":"Sci. Rep."},{"key":"2037_CR36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ajo.2021.11.002","volume":"234","author":"G Beykin","year":"2022","unstructured":"Beykin, G. et al. Phase 1b randomized controlled study of short course topical recombinant human nerve growth factor (rhNGF) for neuroenhancement in glaucoma: safety, tolerability, and efficacy measure outcomes. Am. J. Ophthalmol. 234, 223\u2013234 (2022).","journal-title":"Am. J. Ophthalmol."},{"key":"2037_CR37","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1136\/bjophthalmol-2020-316781","volume":"106","author":"M Talib","year":"2022","unstructured":"Talib, M. et al. CRB1-associated retinal dystrophies in a Belgian cohort: genetic characteristics and long-term clinical follow-up. Br. J. Ophthalmol. 106, 696\u2013704 (2022).","journal-title":"Br. J. Ophthalmol."},{"key":"2037_CR38","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/0002-9394(85)90351-4","volume":"99","author":"EL Berson","year":"1985","unstructured":"Berson, E. L., Sandberg, M. A., Rosner, B., Birch, D. G. & Hanson, A. H. Natural course of retinitis pigmentosa over a three-year interval. Am. J. Ophthalmol. 99, 240\u2013251 (1985).","journal-title":"Am. J. Ophthalmol."},{"key":"2037_CR39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0886-3350(89)80002-1","volume":"15","author":"LF Jindra","year":"1989","unstructured":"Jindra, L. F. & Zemon, V. Contrast sensitivity testing: a more complete assessment of vision. J. Cataract Refract Surg. 15, 141\u2013148 (1989).","journal-title":"J. Cataract Refract Surg."},{"key":"2037_CR40","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","volume":"119","author":"CM Mangione","year":"2001","unstructured":"Mangione, C. M. et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch. Ophthalmol. 119, 1050\u20131058 (2001).","journal-title":"Arch. Ophthalmol."},{"key":"2037_CR41","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamaneurol.2019.3762","volume":"77","author":"R Howard","year":"2020","unstructured":"Howard, R. et al. Minocycline at 2 different dosages vs placebo for patients with mild Alzheimer disease: a randomized clinical trial. JAMA Neurol. 77, 164\u2013174 (2020).","journal-title":"JAMA Neurol."},{"key":"2037_CR42","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1212\/01.WNL.0000125321.92112.7E","volume":"62","author":"PH Gordon","year":"2004","unstructured":"Gordon, P. H. et al. Placebo-controlled phase I\/II studies of minocycline in amyotrophic lateral sclerosis. Neurology 62, 1845\u20131847 (2004).","journal-title":"Neurology"},{"key":"2037_CR43","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1001\/jamaophthalmol.2024.0118","volume":"142","author":"TDL Keenan","year":"2024","unstructured":"Keenan, T. D. L. et al. Phase 2 trial evaluating minocycline for geographic atrophy in age-related macular degeneration. JAMA Ophthalmol. 142, 345\u2013355 (2024).","journal-title":"JAMA Ophthalmol."},{"key":"2037_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10633-014-9473-7","volume":"130","author":"DL McCulloch","year":"2015","unstructured":"McCulloch, D. L. et al. ISCEV Standard for full-field clinical electroretinography (2015 update). Doc. Ophthalmol. 130, 1\u201312 (2015).","journal-title":"Doc. Ophthalmol."},{"key":"2037_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ophtha.2017.08.002","volume":"125","author":"NYQ Tan","year":"2018","unstructured":"Tan, N. Y. Q. et al. The effect of testing reliability on visual field sensitivity in normal eyes: the Singapore Chinese Eye Study. Ophthalmology 125, 15\u201321 (2018).","journal-title":"Ophthalmology"},{"key":"2037_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/bjo.88.1.11","volume":"88","author":"K Pesudovs","year":"2004","unstructured":"Pesudovs, K., Hazel, C. A., Doran, R. M. L. & Elliott, D. B. The usefulness of Vistech and FACT contrast sensitivity charts for cataract and refractive surgery outcomes research. Br. J. Ophthalmol. 88, 11\u201316 (2004).","journal-title":"Br. J. Ophthalmol."},{"key":"2037_CR47","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/0042-6989(70)90123-9","volume":"10","author":"PR Kinnear","year":"1970","unstructured":"Kinnear, P. R. Proposals for scoring and assessing the 100-Hue test. Vis. Res. 10, 423\u2013433 (1970).","journal-title":"Vis. Res."},{"key":"2037_CR48","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1136\/bjophthalmol-2018-313669","volume":"103","author":"M Iftikhar","year":"2019","unstructured":"Iftikhar, M. et al. Classification of disease severity in retinitis pigmentosa. Br. J. Ophthalmol. 103, 1595\u20131599 (2019).","journal-title":"Br. J. Ophthalmol."},{"key":"2037_CR49","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/09286580590967763","volume":"12","author":"AB Toprak","year":"2005","unstructured":"Toprak, A. B., Eser, E., Guler, C., Baser, F. E. & Mayali, H. Cross-validation of the Turkish version of the 25-item National Eye Institute Visual Functioning Questionnaire (NEI-VFQ 25). Ophthalmic Epidemiol. 12, 259\u2013269 (2005).","journal-title":"Ophthalmic Epidemiol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02037-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02037-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02037-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:02:37Z","timestamp":1733270557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-024-02037-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2037"],"URL":"https:\/\/doi.org\/10.1038\/s41392-024-02037-2","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"24 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"339"}}